Lv2
130 积分 2023-07-09 加入
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study
11天前
已完结
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC
1个月前
已完结
Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development
2个月前
已完结
Overall survival with amivantamab-lazertinib in EGFR-mutated advanced NSCLC
2个月前
已完结
Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC
2个月前
已关闭
MET Enhances Amivantamab Binding to EGFR and Antibody‐Dependent Cellular Toxicity
2个月前
已完结
The Critical Role of Passive Permeability in Designing Successful Drugs
2个月前
已完结
Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial
2个月前
已完结
New Horizons in the Treatment of Osteosarcoma
3个月前
已完结
皖公网安备34019202002308
